KRAS and neoplasm: Although our preclinical data suggest a threshold for the KRAS WT CN of 7 that predicts sensitivity to BI-2493, retrospective analysis of tumor samples derived from patients treated with a pan-KRAS inhibitor will be required to further validate this threshold in the clinical setting.